ARTICLE | Company News
Canbex Therapeutics, Ipsen deal
March 9, 2015 7:00 AM UTC
Canbex granted Ipsen an exclusive option to acquire Canbex. The option is exercisable following the completion of a Phase IIa trial of VSN16R. The anti-spastic oral small molecule has completed a Pha...